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SerOBJECTIVES The SOURCE XT Registry (Edwards SAPIEN XT Aortic Bioprosthesis Multi-Region Outcome Registry)
assessed the use and clinical outcomes with the SAPIEN XT (Edwards Lifesciences, Irvine, California) valve in the real-
world setting.
BACKGROUND Transcatheter aortic valve replacement is an established treatment for high-risk/inoperable patients
with severe aortic stenosis. The SAPIEN XT is a balloon-expandable valve with enhanced features allowing delivery via a
lower proﬁle sheath.
METHODS The SOURCE XT Registry is a prospective, multicenter, post-approval study. Data from 2,688 patients at 99
sites were analyzed. The main outcome measures were all-cause mortality, stroke, major vascular complications,
bleeding, and pacemaker implantations at 30-days and 1 year post-procedure.
RESULTS The mean age was 81.4  6.6 years, 42.3% were male, and the mean logistic EuroSCORE (European System
for Cardiac Operative Risk Evaluation) was 20.4  12.4%. Patients had a high burden of coronary disease (44.2%),
diabetes (29.4%), renal insufﬁciency (28.9%), atrial ﬁbrillation (25.6%), and peripheral vascular disease (21.2%).
Survival was 93.7% at 30 days and 80.6% at 1 year. At 30-day follow-up, the stroke rate was 3.6%, the rate of major
vascular complications was 6.5%, the rate of life-threatening bleeding was 5.5%, the rate of new pacemakers was
9.5%, and the rate of moderate/severe paravalvular leak was 5.5%. Multivariable analysis identiﬁed nontransfemoral
approach (hazard ratio [HR]: 1.84; p < 0.0001), renal insufﬁciency (HR: 1.53; p < 0.0001), liver disease (HR: 1.67;
p ¼ 0.0453), moderate/severe tricuspid regurgitation (HR: 1.47; p ¼ 0.0019), porcelain aorta (HR: 1.47; p ¼ 0.0352),
and atrial ﬁbrillation (HR: 1.41; p ¼ 0.0014), with the highest HRs for 1-year mortality. Major vascular complications
and major/life-threatening bleeding were the most frequently seen complications associated with a signiﬁcant increase
in 1-year mortality.
CONCLUSIONS The SOURCE XT Registry demonstrated appropriate use of the SAPIEN XT THV in the ﬁrst year
post-commercialization in Europe. The safety proﬁle is sustained, and clinical beneﬁts have been established in the
real-world setting. (SOURCE XT Registry; NCT01238497) (J Am Coll Cardiol Intv 2015;8:657–69) © 2015 by the
American College of Cardiology Foundation.m the *Medical Clinic IV, Department of Cardiology, Municipal Hospital Karlsruhe, Karlsruhe, Germany; yInstitut Hospitalier
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658T ranscatheter aortic valve replacement(TAVR) has revolutionized the treat-ment of severe degenerative aortic ste-
nosis in elderly patients and has become a
routine procedure in more than 40 countries
around the world (1,2). The ﬁrst-generation
balloon-expandable SAPIEN transcatheter heart
valve (THV) (Edwards Lifesciences, Irvine, Cali-
fornia) was fully approved for commercial use
via the transfemoral (TF) or transapical (TA)
approach in the European Union and United
States in January 2008 andOctober 2012, respec-
tively. The safety proﬁle and clinical beneﬁts
of the SAPIEN valve were demonstrated in
the SOURCE Registry (3,4). The second-generation SAPIEN XT valve incorporated technological
developments, including a cobalt-chromium stent and
a lower proﬁle delivery system. Following CE mark
approval of the SAPIEN XT valve, the SOURCE XT Reg-
istry (Edwards SAPIEN XT Aortic Bioprosthesis Multi-
Region Outcome Registry) was initiated to study the
pattern of use during the ﬁrst years of commercializa-
tion, as TAVR moved beyond the clinical trial care
and evolved to a routine treatment. The SOURCE XT
Registry was designed to further assess safety and efﬁ-
cacy of the SAPIEN XT valve according to the newly
developed Valve Academic Research Consortium deﬁni-
tions (5). This paper describes the baseline risk factors
in the patient population undergoing TAVR with the
balloon-expandable valve and the clinical outcomes at
30 days and 1 year after implantation of the SAPIEN
XT valve in a real-world setting.
METHODS
REGISTRY. The SOURCE XT study is a multicenter,
prospective, consecutively enrolled, observational
registry (Online Appendix). Data for all patients con-
secutively treated with the commercially available
SAPIEN XT valve at 99 sites in 17 countries were used
for this analysis. Patients treated with other valves
were not included. One site, which enrolledE XT Registry was funded by Edwards Lifesciences. Dr. Schymik
rds Lifesciences. Dr. Lefèvre is a proctor for Edwards Lifescience
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received October 5, 2014; accepted October 8, 2014.6 patients, was excluded for noncompliance with
regulatory requirements. Additionally, 9 patients
from participating sites were excluded for not
providing an informed consent form. From a total of
2,706 consented patients enrolled between July 2010
and November 2011, no procedure was attempted in
18 patients; therefore, 2,688 patients remained in the
ﬁnal cohort and were included in this analysis
(Figure 1). Patient data were collected at discharge,
30 days, and 12 months post-implantation.
DEVICES AND PROCEDURE. The SAPIEN XT valve
is composed of a nickel-cobalt chromium stent
frame, a trileaﬂet bovine pericardial tissue valve,
and a polyethylene-terephthalate fabric skirt. The
valve was available in sizes of 23 and 26 mm for all
delivery approaches. The 29-mm valve was avail-
able for the TA approach only. The NovaFlex
delivery system (Edwards Lifesciences), which in-
cludes an integrated distal tip and a lower crossing
proﬁle, was used for the TF approach with 18-F
(23-mm valve) or 19-F (26-mm valve) introducer
sheaths. The Ascendra delivery system (Edwards
Lifesciences) was used for the transapical access.
PATIENT SELECTION. High surgical risk patients
with severe symptomatic aortic stenosis, were
deemed eligible for the procedure. Logistic Euro-
SCORE I (European System for Cardiac Operative Risk
Evaluation) was used as a general tool for a risk
assessment; however, the ﬁnal decision was made by
the heart team, considering all underlying conditions.
Examinations were on the basis of standards of care
for TAVR at each participating site. Annulus diameter
was measured by computed tomography scans or
transthoracic and/or transesophageal echocardio-
graphy; however, only transthoracic echocardio-
graphic data were required.
DATA COLLECTION. All data were entered in the
electronic data capture system and monitored.
All adverse events were adjudicated according tois a proctor for and has received speaker honoraria
s; and has received minor fees from Symetis, Med-
from Edwards Lifesciences and Abbott; and is on the
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FIGURE 1 Patient Disposition to 1-Year Follow-Up
Cascade diagram showing patient disposition from enrollment to procedure and at
each follow-up interval to 1 year. *Reasons for exclusion: no informed consent, site
noncompliance, and no procedure performed. **4 patients who missed 30-day visit were
reached at 1-year follow-up. LTFU ¼ lost to follow-up.
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659Valve Academic Research Consortium criteria by an
independent clinical events committee. All data used
in the analysis are as of June 21, 2013.
ENDPOINT DEFINITIONS. All study endpoints were
deﬁned per the Valve Academic Research Con-
sortium 1 (5). The principal outcome measures in
the SOURCE XT Registry are all-cause death,
cardiac death, and stroke. Secondary measures
include major vascular complications, major and
life-threatening bleeding, acute kidney injury,
permanent pacemaker insertion, procedure- and
device-related complications, functional status, and
echocardiographic assessment of the valve and heart
function. No echocardiography core laboratory was
used; therefore, all echocardiographic data were site
reported. Procedural success was deﬁned as 1 valve
implanted at the intended site by 1 attempted pro-
cedure and no procedure-related death within 48 h
from implantation. Device success was further
deﬁned as a successfully delivered valve with
gradient #20 mm Hg and no moderate or severe
aortic regurgitation at discharge. A patient was
considered frail if any of the following condi-
tions were met: 1) 15-ft walk time $6 s; 2) grip
strength <16 kg; 3) Katz index #4.
STATISTICAL ANALYSIS. Continuous variables were
presented as mean  SD and comparisons were per-
formed with the 2-sample Student t test. Categorical
data were presented as percents and comparisons
between groups done by the Fisher exact or chi-
square test. Paired comparisons of continuous and
categorical variables were done by the paired Student
t test and the McNemar test, respectively.
Survival analysis was performed by Kaplan-Meier
method. Survival curves for time-to-event variables
were constructed with the use of Kaplan-Meier
estimates and were compared using the log-rank
test.
Univariable Cox proportional hazard regression
was performed to determine baseline and procedural
predictors of 1-year mortality. All independent pre-
dictors with a p value <0.1 were entered in the
multivariable model with stepwise procedure. The
signiﬁcance level for entry/exit was set at 0.10.
Differences were considered statistically signiﬁ-
cant when the p value was <0.05. All statistical ana-
lyses were performed with the use of SAS software,
version 9.3 (SAS Institute, Cary, North Carolina).
The corresponding authors had full access to the
reported data and takes responsibility for the integ-
rity of the data presented. All authors have read and
agreed to the paper as written.RESULTS
BASELINE CHARACTERISTICS AND RISK ASSESSMENT.
The baseline characteristics are presented in Table 1.
The mean age was 81.4  6.6 years, more patients
were female, and the majority of patients had se-
vere functional limitations. Severe aortic stenosis
was evident with a mean gradient of 47.6  16.2
mm Hg and mean effective oriﬁce area (EOA) of 0.7
 0.2 cm2. Severe pulmonary hypertension was
present in 25.5% of patients, moderate/severe
tricuspid regurgitation in 14.1%, and moderate/se-
vere mitral regurgitation in 19.8%. Patients had a
high burden of coronary artery disease, atrial ﬁbril-
lation, diabetes, peripheral vascular disease, and
renal insufﬁciency. This resulted in a mean logistic
EuroSCORE of 20.4  12.4% (median, 17.6%; inter-
quartile range, 11.4% to 27.0%), indicating signiﬁ-
cant surgical risk. Additional markers of increased
risk of surgery were common: 83.5% of patients
were frail, 6.5% had a porcelain aorta, 2.9% had
severe liver disease, 1.6% had oxygen-dependent
pulmonary disease, and 3.9% had a left ventricular
ejection fraction of #30%. The vast majority of
TABLE 1 Baseline Patient Characteristics
All Patients
(N ¼ 2,688)
Transfemoral
(n ¼ 1,685)
Transapical
(n ¼ 894) p Value
Age, yrs 81.4  6.6 82.0  6.5 80.1  6.4 <0.0001
Female 1,550/2,688 (57.7) 1,085/1,685 (64.4) 408/894 (45.6) <0.0001
Logistic EuroSCORE, % 2,676, 20.4  12.4 1,682, 19.8  11.6 887, 21.9  13.7 <0.0001
STS score, % 2,377, 7.9  6.6 1436, 8.0  6.8 841, 7.9  6.3 0.8300
NYHA functional class
I/II 619/2,676 (23.1) 377/1,676 (22.5) 211/891 (23.7) 0.5213
III/IV 2,057/2,676 (76.9) 1,299/1,676 (77.5) 680/891 (76.3)
Angina CCS classes II–IV 588/2,663 (22.1) 389/1,668 (20.9) 226/887 (25.4) 0.0018
CAD 1,188/2,688 (44.2) 667/1,685 (39.6) 456/894 (51.0) <0.0001
MI 406/2,688 (15.1) 205/1,685 (12.2) 187/894 (20.9) <0.0001
Previous PCI 819/2,688 (30.5) 460/1,685 (27.3) 331/894 (37.0) <0.0001
CABG 431/2,688 (16.0) 204/1,685 (12.1) 218/894 (24.4) <0.0001
Hyperlipidemia 1,507/2,688 (56.1) 902/1,685 (53.5) 542/894 (60.6) 0.0006
Hypertension 2,175/2,688 (80.9) 1,332/1,685 (79.1) 767/894 (85.8) <0.0001
Atrial ﬁbrillation 685/2,676 (25.6) 395/1,678 (23.5) 271/889 (30.5) 0.0002
Pacemaker/ICD implantation 304/2,688 (11.3) 170/1,685 (10.1) 119/894 (13.3) 0.0152
Peripheral vascular disease 569/2,687 (21.2) 248/1,684 (14.7) 295/894 (33.0) <0.0001
Previous peripheral intervention 65/2,687 (2.4) 20/1,684 (1.2) 43/894 (4.8) <0.0001
Porcelain aorta 174/2,687 (6.5) 71/1,684 (4.2) 98/894 (11.0) <0.0001
Pulmonary artery pressure $55 mm Hg 481/1,884 (25.5) 326/1,218 (26.8) 141/588 (24.0) 0.2078
COPD 546/2,687 (20.3) 327/1,684 (19.4) 202/894 (22.6) 0.0582
Pulmonary disease, oxygen dependent 43/2,687 (1.6) 31/1,684 (1.8) 9/894 (1.0) 0.1311
Diabetes 791/2,688 (29.4) 452/1,685 (26.8) 304/894 (34.0) 0.0002
Stroke 225/2,688 (8.4) 123/1,685 (7.3) 94/894 (10.5) 0.0058
TIA 120/2,687 (4.5) 76/1,684 (4.5) 40/894 (4.5) >0.9999
Chest deformities 24/2,687 (0.9) 18/1,684 (1.1) 4/894 (0.4) 0.1186
Liver disease 79/2,688 (2.9) 52/1,685 (3.1) 25/894 (2.8) 0.7171
Renal insufﬁciency/failure or dialysis 777/2,687 (28.9) 432/1,684 (25.7) 327/894 (36.6) <0.0001
Endocarditis 30/2,688 (1.1) 19/1,685 (1.1) 10/894 (1.1) >0.9999
Cancer 480/2,688 (17.9) 300/1,685 (17.8) 153/894 (17.1) 0.7035
Frail conditions
Katz Index #4 427/2,115 (20.2) 258/1,292 (20.0) 161/724 (22.2) 0.2301
Grip strength <16 kg 407/1,649 (24.7) 269/977 (27.5) 116/580 (20.0) 0.0008
15-ft walk time $6 s 1,008/1,351 (74.6) 613/802 (76.4) 340/ 474 (71.7) 0.0626
Frail 1,365/1,634 (83.5) 844/985 (85.7) 457/566 (80.7) 0.0120
Echocardiographic data
Mean gradient, mm Hg 2,503, 47.6  16.2 1,580, 49.2  16.5 821, 45.0  15.5 <0.0001
EOA, cm2 2,253, 0.7  0.2 1,402, 0.7  0.2 751, 0.7  0.2 <0.0001
Pulmonary artery pressure, mm Hg 1,884, 44.9  14.9 1,218, 46.0  14.8 588, 43.1  15.3 0.0001
LVEF, % 2,536, 54.4  12.5 1,594, 55.1  12.5 837, 53.3  12.3 0.0008
LVEF <30% 100/2,536 (3.9) 57/1,594 (3.6) 32/837 (3.8) 0.3080
Moderate/severe mitral
regurgitation
519/2,615 (19.8) 345/1,633 (21.1) 161/880 (18.3) 0.0953
Moderate/severe tricuspid
regurgitation
343/2,432 (14.1) 232/1,512 (15.3) 109/827 (13.2) 0.1593
Values are mean  SD; n/N (%); or n, mean  SD.
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CCS ¼ Canadian Cardiovascular Society; COPD ¼ chronic obstructive pulmonary disease; EOA ¼ effective
oriﬁce area; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; ICD ¼ implantable cardioverter-deﬁbrillator; LVEF ¼ left ventricular ejection fraction;
MI¼myocardial infarction; NYHA¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; STS ¼ Society of Thoracic Surgeons; TIA¼ transient ischemic attack.
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660patients had at least 1 of these risk factors. There
were signiﬁcant differences in baseline characteris-
tics between patients undergoing TAVR via the TF
and TA approaches. Overall, the patients who had
the TA were at higher risk (Table 1).PROCEDURE AND INDEX HOSP ITAL IZAT ION.
Procedural data are summarized in Table 2. The im-
plantation approach was TF in 62.7% and TA in 33.3%.
Only a small proportion of patients were treated with
the TAo or subclavian approach. In 24.3% of TF
TABLE 2 Procedural Data, Procedural Complications, and Index Hospitalization
All Patients
(N ¼ 2,688)
Transfemoral
(n ¼ 1,685)
Transapical
(n ¼ 894) p Value
Procedural data
Implantation approach
Transapical 894/2,688 (33.3) — 894/2,688 (33.3)
Transfemoral 1,685/2,688 (62.7) 1,685/2,688 (62.7) —
Subclavian 8/2,688 (0.3) — —
Transaortic 101/2,688 (3.8) — —
Procedure room <0.0001
Cath lab 1,426/2,686 (53.1) 1,093/1,684 (64.9) 278/893 (31.1)
Hybrid room 1,030/2,686 (38.3) 548/1,684 (32.5) 430/893 (48.2)
Surgical OR 230/2,686 (8.6) 43/1,684 (2.6) 185/893 (20.7)
Type of anesthesia <0.0001
General 1,801/2,501 (72.0) 848/1,536 (55.2) 850/861 (98.7)
Conscious sedation/local/
regional
700/2,501 (28.0) 688/1,536 (44.8) 11/861 (1.3)
Pre-implantation BAV 2,599/2,685 (96.8) 1,659/1,685 (98.5) 832/891 (93.4) <0.0001
No. of balloon inﬂations 1.2  0.5 1619, 1.2  0.6 801, 1.1  0.4 <0.0001
None 23/2,528 (0.9) 12/1,619 (0.7) 10/801 (1.2)
1 2,198/2,528 (86.9) 1,358/1,619 (83.9) 735/801 (91.8)
$2 307/2,528 (12.1) 249/1,619 (15.4) 56/801 (7.0)
Valve size, mm <0.0001
23 1135/2,675 (42.4) 801/1680 (47.7) 300/886 (33.9)
26 1305/2,675 (48.8) 879/1680 (52.3) 374/886 (42.2)
29 235/2,675 (8.8) 0/1,680 (0.0) 212/886 (23.9)
Post-deployment balloon dilations <0.0001
None 2114/2,674 (79.1) 1,400/1,675 (83.6) 650/890 (73.0)
1 510/2,674 (19.1) 254/1,675 (15.2) 211/890 (23.7)
$2 50/2,674 (1.9) 21/1,675 (1.3) 29/890 (3.3)
Total procedure time, min 2,652, 84.0  54.9 1,655, 79.3  51.9 888, 89.3  56.9 <0.0001
Fluoroscopy time, min 2,613, 12.0  20.2 1,640, 14.8  20.7 865, 7.3  19.3 <0.0001
Volume of contrast used, ml 2,642, 123.8  98.2 1,659, 141.2  103.5 875, 93.4  81.3 <0.0001
Valve not implanted 22/2,687 (0.8) 10/1,685 (0.6) 12/893 (1.3) 0.0692
Procedural success 2,567/2,688 (95.5) 1,624/1,685 (96.4) 844/894 (94.4) 0.0244
Device success 1,862/2,105 (88.5) 1,241/1,443 (86.0) 544/644 (84.5) 0.3813
Procedural complications
Procedure-related death 53/2,688 (2.0) 26/1,685 (1.5) 22/894 (2.5) 0.1248
Procedure-related stroke 54/2,688 (2.0) 38/1,685 (2.3) 15/894 (1.7) 0.3826
Annulus rupture or dissection 11/2,688 (0.4) 8/1,685 (0.5) 1/894 (0.1) 0.1757
Aortic dissection 14/2,688 (0.5) 8/1,685 (0.5) 1/894 (0.1) 0.1757
Cardiac tamponade 24/2,688 (0.9) 20/1,685 (1.2) 3/894 (0.3) 0.0280
Pericardial effusion 34/2,688 (1.3) 24/1,685 (1.4) 9/894 (1.0) 0.4627
Coronary occlusion 12/2,688 (0.4) 6/1,685 (0.4) 4/894 (0.4) 0.7456
Mitral valve injury 8/2,688 (0.3) 2/1,685 (0.1) 6/894 (0.7) 0.0239
Conversion to conventional surgery 11/2,688 (0.4) 5/1,684 (0.3) 5/893 (0.6) 0.3296
New permanent pacemaker 162/2,688 (6.0) 96/1,685 (5.7) 64/894 (7.2) 0.1456
New-onset atrial ﬁbrillation
(at discharge)
121/2,459 (4.9%) 51/1,618 (3.2%) 70/841 (8.3%) <0.0001
Values are n/N (%); mean  SD; n, mean  SD; or n (%).
BAV ¼ bicuspid aortic valve; OR ¼ operating room.
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661patients, access was achieved by surgical cut-down,
whereas in 75.7%, the access was percutaneous. In
47.9% of TF patients, the vessel diameter was #7 mm
(mean, 7.6  1.3 mm). Pre-implantation balloon aortic
valvuloplasty, usually with 1 balloon inﬂation, was
performed in the vast majority of patients. Only asmall proportion of patients were implanted with the
29-mm valve, as it was initially available for the TA
approach only. Balloon post-deployment dilation was
performed in 20.9%. Valve position was correct at the
intended site in 97.1%, and technical success was
95.5%.
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662The mean duration of hospitalization for the index
procedure was 11.1  9.2 days. The majority of time
was spent in a general ward (8.4  6.2 days), and fewer
days were spent in an intensive care/intermediate
care unit (5.3  6.8 days). Compared with the TF
approach, the TA approach was characterized by
fewer bicuspid aortic valve and more post-dilations, a
longer procedure time, a shorter ﬂuoroscopy time,
and less use of contrast (Table 2).
PROCEDURAL COMPLICATIONS. The most frequently
seen serious procedural complications within 48 h
after valve implantation were major/life-threatening
bleeding and vascular access-related complications
(Table 2). All other severe complications were rare.
The procedure-related mortality rate was 2.0%. The
procedure-related stroke rate was observed in 2.0% of
patients. Annulus rupture and coronary occlusion
occurred in 0.4% each and cardiac tamponade in
0.9%. Valve embolization occurred in 0.7% (n ¼ 18);
one-half of all embolization’s traveled to the aorta
and the other half to the left ventricle. Valve-in-valve
implantation due to procedural complication was
needed in 29 patients (1.1%). Conversion to conven-
tional surgery was required only in a few patients
(0.4%). In general, the procedural complications were
similar for the TF and TA approaches; however, mitral
valve injury and atrial ﬁbrillation occurred more
frequently with the TA approach (Table 2).
CLINICAL OUTCOMES. At 30-days post-implantation,
the overall mortality rate was 6.3% (4.2% TF/10.0%TABLE 3 Clinical Outcomes at 30 Days and 1 Year After TAVR
Complication
Kaplan-Meier Event Rate at
30 Days
All Patients
(N ¼ 2,688)
Transfemoral
(n ¼ 1,685)
Transapical
(n ¼ 894)
All-cause death 6.3 4.2 10.0
Cardiac death 3.0 1.7 5.7
Stroke 3.6 3.4 4.2
All vascular complications 15.8 21.2 5.7
Major 6.5 7.9 3.5
All bleeding 19.7 15.1 27.0
Life-threatening 5.5 3.8 8.3
Major 10.2 7.7 13.9
Major/life-threatening 14.9 10.9 20.9
Myocardial infarction 0.6 0.4 1.1
Acute kidney injury 17.8 11.9 28.1
Rehospitalizations 6.4 4.9 8.9
Endocarditis 0.2 0.1 0.2
New permanent pacemaker 9.5 8.7 11.6
New-onset atrial ﬁbrillation 5.3 3.3 8.9
Values are % unless otherwise indicated.
TAVR ¼ transcatheter aortic valve replacement.TA) and 3.6% had a stroke (Table 3). Major/life-
threatening bleeding had occurred in 14.9%, major
vascular complications in 6.5%, and acute kidney
injury in 17.8%. Permanent pacemakers were
implanted in 9.5% of patients.
At 1-year follow-up, an additional 2.7% had had a
stroke, an additional 1.5% had a new pacemaker
implanted, and an additional 13.1% of patients had
died. Clinical outcomes with the TF and TA ap-
proaches are presented in Table 3. The TA approach
was associated with higher mortality and signiﬁcantly
more bleeding and acute kidney injury, whereas
the TF approach had a signiﬁcantly higher rate of
vascular complications.
There were a total of 515 deaths, 124 of which
occurred within the ﬁrst 14 days, 44 within 15 to
30 days, and 347 within 1 month to 1 year after TAVR.
Congestive heart failure, multiple organ failure, and
cardiac arrest were the leading causes of death within
the ﬁrst 30 days (17.3%, 15.5%, and 9.5%, respec-
tively) and thereafter at 1 year (13.8%, 12.2%, and
8.6%, respectively).
PREDICTORS OF 1-YEAR MORTALITY. The 1-year
Kaplan-Meier survival curves for the entire patient
cohort and by approach are shown in Figures 2A
and 2B, respectively. The relationship between
logistic EuroSCORE and 1-year survival after TAVR
was examined (Figure 2C). In patients with a Euro-
SCORE $15, the 1-year survival rate was signiﬁcantly
lower than in patients with a logistic EuroSCOREKaplan-Meier Event Rate at
1 Year
p Value
All Patients
(N ¼ 2,688)
Transfemoral
(n ¼ 1,685)
Transapical
(n ¼ 894) p Value
<0.0001 19.4 15.0 27.1 <0.0001
<0.0001 9.5 6.7 14.7 <0.0001
0.3290 6.3 5.6 7.9 0.0473
<0.0001 17.1 22.0 8.2 <0.0001
<0.0001 7.2 8.3 4.6 0.0003
<0.0001 22.9 18.2 30.3 <0.0001
<0.0001 6.7 4.5 10.1 <0.0001
<0.0001 12.0 9.2 16.2 <0.0001
<0.0001 17.2 13.0 23.6 <0.0001
0.0630 1.8 1.5 2.6 0.0510
<0.0001 20.6 14.7 31.0 <0.0001
<0.0001 29.5 25.5 36.8 <0.0001
0.4910 1.1 1.0 1.4 0.4085
0.0212 11.0 10.0 13.4 0.0121
<0.0001 7.9 5.6 12.5 <0.0001
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663<15 (78.9% vs. 83.4%; p ¼ 0.003). The 1-year survival
rate for the TF patients (85.0%) was signiﬁcantly
better than for the TA (72.9%; p < 0.0001) and
transaortic (73.9%; p ¼ 0.0011) patients. The most
frequent TAVR complications (major vascular com-
plications and major/life-threatening bleeding) were
undesirably associated with the 1-year survival
(Figures 2D and 2E). Although patients with no
major vascular complications had an 81.8% sur-
vival rate at 1 year, those with major vascular compli-
cations had a signiﬁcantly lower chance to survive
(61.6%; p < 0.0001). Similarly, patients with major/
life-threatening bleeding had signiﬁcantly worse
1-year survival rates compared with those with no
major/life-threatening bleeding (66.3% vs. 83.1%;
p < 0.0001).
Univariate predictors of 1-year mortality are shown
in Table 4, and the multivariate predictors are pre-
sented in Figure 3. Non-TF access was a signiﬁcant
predictor of mortality. Baseline liver disease and
renal insufﬁciency/failure were associated with theFIGURE 2 Kaplan-Meier Survival Analyses at 1 Year
(A) Overall/cardiac survival for all SOURCE XT patients. (B) Overall surviv
EuroSCORE (European System for Cardiac Operative Risk Evaluation [ES])
survival: major/life-threatening bleeding (Bldg.) within 30 days.highest risk (>50%) of mortality. Cardiovascular
conditions such as moderate/severe tricuspid re-
gurgitation, porcelain aorta, atrial ﬁbrillation, coro-
nary artery disease, and New York Heart Association
(NYHA) functional class III/IV increased the risk
of death to between 20% and 50%. Cancer and
chronic obstructive pulmonary disease increased
the risk of 1 year mortality by 33% and 31%,
respectively. Age, logistic EuroSCORE, lower mean
gradient, and body mass index were signiﬁcant
multivariate predictors of 1-year mortality. How-
ever, they individually only increased the risk
by <5%.
FUNCTIONAL CLASS, SYMPTOMS, AND QUALITY OF
LIFE. At baseline, the majority of patients were in
NYHA functional class III or IV; however, at 30-day
and 1-year follow-up, the majority of the patients
showed signiﬁcant improvement and were in NYHA
functional class I or II (Figure 4A, all patients). Using
paired comparisons, the proportion of patients withal: transfemoral (TF), transapical (TA), and transaortic (Tao) access. (C) Overall survival logistic
<15 and$15. (D) Overall survival: major vascular complications (VC) within 30 days. (E) Overall
TABLE 4 Univariable Proportional Hazard Regression for 1-Year Mortality
Signiﬁcant Predictors N HR (95% CI) p Value
Baseline factors
Logistic EuroSCORE, % 2,676 1.0228 (1.0166–1.0290) <0.0001
Renal insufﬁciency/failure 2,687 1.6798 (1.4070–2.0056) <0.0001
Worse Katz Index 2,115 1.1750 (1.1095–1.2444) <0.0001
Atrial ﬁbrillation 2,676 1.6541 (1.3793–1.9836) <0.0001
Tricuspid regurgitation (moderate/severe) 2,432 1.7359 (1.3904–2.1672) <0.0001
BMI 2,684 0.9581 (0.9399–0.9766) <0.0001
Mean gradient 2,503 0.9873 (0.9815–0.9932) <0.0001
Coronary artery disease 2,688 1.3919 (1.1710–1.6545) 0.0002
Pulmonary disease/COPD 2,687 1.4292 (1.1732–1.7410) 0.0004
NYHA functional class III/IV 2,676 1.5032 (1.1963–1.8889) 0.0005
LVEF, % 2,536 0.9881 (0.9813–0.9950) 0.0007
Previous myocardial infarction 2,688 1.4001 (1.1246–1.7431) 0.0026
Peripheral vascular disease 2,687 1.3201 (1.0826–1.6096) 0.0061
Female 2,688 0.7965 (0.6701–0.9469) 0.0099
Liver disease 2,688 1.6854 (1.1188–2.5389) 0.0125
Mitral regurgitation (moderate/severe) 2,615 1.2972 (1.0550–1.5950) 0.0136
Age, yrs 2,688 1.0162 (1.0021–1.0304) 0.0238
Pacemaker/ICD implanted 2,688 1.3171 (1.0267–1.6895) 0.0302
Pulmonary hypertension 2,687 1.2203 (1.0055–1.4812) 0.0439
Cancer 2,688 1.2168 (0.9835–1.5055) 0.0708
Porcelain aorta 2,687 1.3099 (0.9555–1.7958) 0.0935
Previous PCI 2,688 1.1342 (0.9436–1.3633) 0.1796
Previous stroke 2,688 1.2152 (0.9101–1.6226) 0.1864
Diabetes 2,688 1.1308 (0.9394–1.3611) 0.1938
Hypoalbuminemia 2,688 0.8529 (0.4693–1.5501) 0.6017
Hypertension 2,688 1.0537 (0.8433–1.3165) 0.6454
CABG 2,688 1.0323 (0.8171–1.3041) 0.7900
Syncope 2,686 1.0186 (0.7963–1.3029) 0.8835
Procedural factors
Delivery approach (non-TF) 2,688 1.9790 (1.6648–2.3526) <0.0001
Procedure time 2,652 1.0042 (1.0027–1.0056) <0.0001
Anesthesia (general vs. nongeneral) 2,501 0.6361 (0.5099–0.7935) <0.0001
Procedure location
(cath lab vs. noncath lab)
2,686 0.8073 (0.6792–0.9596) 0.0152
Annulus size 2,296 1.0351 (0.9919–1.0801) 0.1129
Pre-implantation BAV 2,685 0.7267 (0.4697–1.1243) 0.1517
Post-deployment BAV 2,674 1.1485 (0.9356–1.4097) 0.1856
Effective valve area 2,253 1.1134 (0.7262–1.7070) 0.6223
BMI ¼ body mass index; CI ¼ conﬁdence interval; non-TF ¼ nontransfemoral; other abbreviations as in
Tables 1 and 2.
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664NYHA functional class III/IV decreased signiﬁcantly at
both baseline to 30 days (76.1% vs. 9.9%; p < 0.0001),
and baseline to 1 year (75.3% vs. 9.7%; p < 0.0001).
Improvement in NYHA functional class occurred pri-
marily during the ﬁrst 30 days post-valve implanta-
tion and remained unchanged between 30 days and
1 year. Symptoms of angina improved after TAVR
(Figure 4B, all patients). In a paired analysis, the
proportion of patients with angina Canadian Cardio-
vascular Society class II or higher was signiﬁcantly
reduced from baseline to 30 days (22.1% vs. 4.0%;
p < 0.001), and from baseline to 1 year (21.8%vs. 2.8%; p < 0.001). This improvement was sus-
tained between 30 days and 1 year (3.5% vs. 2.8%;
p ¼ 0.1698).
Quality of life improved continuously throughout
the follow-up (Figure 4C, all patients). In a paired
analysis, the improvement in the quality of life EQ-5D
score was 12.4  20.1 at discharge (p < 0.0001) and
17.8  23.9 (p < 0.0001) at 30-day follow-up. The
mean quality of life EQ-5D score increased 40%
(p < 0.0001) at 1-year follow-up.
ECHOCARDIOGRAPHIC DATA. After SAPIEN XT valve
implantation, there was immediate improvement in
both mean gradient and EOA that was sustained
throughout the follow-up (Figures 5A and 5B). The
incidence of paravalvular leak (PVL) and total aortic
regurgitation were very low throughout the entire
follow-up (Figures 5C and 5D). PVL was assessed as
none/trace in the majority of patients at discharge
and throughout the follow up. Mild PVL occurred in
one-fourth of patients. Only a small portion of pa-
tients (between 4.4% and 6.2%) had moderate or
severe PVL throughout the follow-up, and only 0.2%
of patients had severe PVL.DISCUSSION
One of the major objectives of the SOURCE XT
Registry was to evaluate the risk proﬁle of patients
undergoing SAPIEN XT implantation in a real-world
setting, as TAVR matured from a study procedure
in a limited number of well-selected study patients
to a routine treatment available for a broader pop-
ulation. TAVR is emerging as a multidisciplinary
ﬁeld, and the heart team is essential to select the
best treatment for patients with severe degenerative
aortic stenosis (6). The logistic EuroSCORE and/or
Society of Thoracic Surgeons score are still used for
an initial risk assessment. However, both scoring
systems were established as a mortality risk assess-
ment for open cardiac surgery and were shown to be
not well suited for TAVR (7–9). Despite these limi-
tations, a logistic EuroSCORE >15% is still used as an
indication for the SAPIEN XT valve, and the majority
of the SOURCE XT patients met this criterion.
Although this is a product-speciﬁc indication in the
European Union, the European guidelines for TAVR
do not require the use of the EuroSCORE in isola-
tion, but emphasize the critical importance of the
heart team evaluation for patient selection (6).
Several important risk factors such as frailty, severe
liver disease, porcelain aorta, and hostile chest,
which are not considered in any risk score algorithm
(10,11), were present in 95.8% of patients and were
FIGURE 3 Multivariate Predictors of 1-Year Mortality
The forest plot shows the multivariable predictors of 1-year mortality with corresponding hazard ratios and p values. BMI ¼ body mass index;
CI ¼ conﬁdence interval; COPD ¼ chronic obstruction pulmonary disease; NYHA ¼ New York Heart Association; TF ¼ transfemoral.
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665thoroughly examined by the heart teams during the
patient selection process. This underscores the
importance of incorporating the heart team concept,
as described in the European Society of Cardiology/
European Association for Cardiothoracic Surgery
guidelines, especially when a TAVR-speciﬁc risk-
assessment tool is not available (6). The SOURCE XT
Registry was able to conﬁrm the high-risk proﬁle of
patients treated with the SAPIEN XT valve (3). As
noted previously, the TA patients were at higher
surgical risk and presented with more risk factors
and comorbidities.
TAVR was performed transfemorally in 62.7% and
transapically in 33.3% of patients. Only a small pro-
portion of patients were treated with TAo or subcla-
vian approaches, which are considered emerging
approaches for the balloon-expandable valves. The
majority of patients received either the 23-mm or 26-
mm valve, and <10% of patients were treated with
the 29-mm valve. This imbalance in valve sizes was
driven by 29-mm valve availability for TA use only
later during the course of the SOURCE XT Registry.Balloon post-dilation was done in 20.9% of patients
and this was signiﬁcantly lower than the 41% pub-
lished by Daneault et al. (12) for the SAPIEN valve in a
single-center PARTNER (Placement of Aortic Trans-
catheter Valves Trial) experience. The rates of balloon
post-dilation reported in the published data are be-
tween 5% and 41% (13,14), and it is commonly per-
formed to better expand the stent of the THV and
reduce the degree of PVL. However, post-dilation
has been identiﬁed as an independent predictor of
cerebrovascular events (15) andmay be also associated
with complications such as conduction disturbances,
annulus rupture, and coronary occlusion (13,16).
These risks may outweigh the beneﬁts achieved by
reduction in PVL, suggesting that PVL should be
addressed by the improvement in valve design rather
than through post-dilation. From this point of view, it
was reassuring to see that in the SOURCE XT Registry,
the rate of post-dilation was showing a downward
trend.
TAVR was carried out successfully in the
majority of patients, with a technical success rate
FIGURE 4 Clinical Symptom Improvement Throughout 1-Year Follow-up
All SOURCE XT patients. Observations at baseline, 30 days, and 1 year. (A) New York Heart Association (NYHA) functional class. (B) Angina Canadian Cardiovascular
Society (CCS) class. (C) Quality of life (EQ-5D) score.
Schymik et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 5 , 2 0 1 5
The SOURCE XT Registry 1-Year Outcomes A P R I L 2 7 , 2 0 1 5 : 6 5 7 – 6 9
666of 95.5%. Conversion-to-conventional surgery and
valve-in-valve implantation due to complications
was needed in only a few patients. The need for
emergent cardiac surgery in the SOURCE XT Registry
was comparable to the 1.1% incidence reported by
Eggebrecht et al. (17) in a meta-analysis on 9,251
patients. The 30-day all-cause mortality rate was
6.3% in the SOURCE XT Registry and 8.5% in the
SOURCE Registry (3). The reduction in the mortality
observed in the SOURCE XT registry may be asso-
ciated with optimized patient selection, fewer
baseline comorbidities, improved valve design, and
increased learning experience of the operators.
Similar trends were shown in other national regis-
tries (18–20). The FRANCE 2 Registry, which enrolled
3,195 patients between January 2010 and October
2011, reported a 30-day mortality rate of 9.7%, which
was almost 50% higher than that in the SOURCE XT
(18). The U.K. Transcatheter Aortic Valve Implanta-
tion Registry enrolled 870 patients between January
2007 and December 2009 and reported a 30-day
mortality rate of 7.1% (19). The German Aortic
Valve Registry enrolled 3,875 patients (2,694 TF
patients, 1,181 TA patients) in 2011 and reported a
5.1% in-hospital mortality rate for the TF approach
(20), which was slightly higher than the 4.2% 30-day
mortality for the TF access in the SOURCE XT
Registry.The 1-year mortality rate of TF patients in the
SOURCE XT Registry was 15% and is one of the lowest
observed for any THV study in the real-world setting
(4,18,19,21). As expected, the 1-year mortality rate for
the TA approach was higher at 27.6% and can most
likely be attributed to the higher baseline risk typi-
cally seen in this patient population (3). As also shown
by the multivariate prediction model, liver disease
and renal insufﬁciency/failure were the baseline
characteristics with the highest increase in the risk of
mortality, followed by moderate/severe tricuspid
regurgitation, porcelain aorta, atrial ﬁbrillation, cor-
onary artery disease, and severe congestive heart
failure symptoms (NYHA functional class III/IV). On
the one hand, these results demonstrated the strong
correlation between existing comorbidities and 1-year
mortality after TAVR. On the other hand, this also
emphasized the urgent need for the development of a
reliable TAVR-speciﬁc risk-assessment algorithm that
incorporates all the important baseline risk factors.
Mortality after TAVR is not solely driven by the risk
proﬁle of the patients. As shown previously, the more
frequently seen TAVR complications such as major
vascular complications and major or life-threatening
bleeding were associated with a higher mortality rate
(4,22,23). These complications need to become a clear
target for further improvement by better patient
management and, more importantly, through an
FIGURE 5 Echocardiographic Data
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J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 5 , 2 0 1 5 Schymik et al.
A P R I L 2 7 , 2 0 1 5 : 6 5 7 – 6 9 The SOURCE XT Registry 1-Year Outcomes
667improved device design with smaller proﬁle delivery
systems.
The hemodynamic performance of the SAPIEN XT
THV, measured by echocardiography at follow-up,
demonstrated a signiﬁcant and sustained decrease
in the mean gradient and increase in the EOA. As
in previous reports (24), there was no evidence of
any structural valve deterioration with the SAPIEN
XT THV, although longer follow-up is required to
understand the valve durability. The occurrence of
PVL represents a signiﬁcant limitation of TAVR,
particularly when expanding this treatment for
intermediate-risk patients is contemplated (25). In
the SOURCE XT Registry, PVL at 1 year was none/tracein the majority of patients (69.7%), mild in 24.1%, and
moderate or severe in 6.2%. The PVL assessment in
the SOURCE XT Registry was conducted by echocar-
diographers on-site rather than an echocardiography
core laboratory. Given the lack of standardized
methods to assess PVL even across echocardiography
core laboratories, SOURCE XT offered a real-life
assessment of this concerning issue with trans-
catheter valves. This registry conﬁrmed the low rates
of signiﬁcant PVL with the SAPIEN XT valve and
clearly demonstrated that it remained stable
throughout follow-up. Although moderate/severe
PVL affected only a small portion of the treated pa-
tients, its association with mortality warrants further
PERSPECTIVES
WHAT IS KNOWN: In multiple randomized trials,
TAVR has been proved to be a safe and effective
treatment for high-risk and inoperable patients with
severe degenerative aortic stenosis.
WHAT IS NEW: The SOURCE XT Registry is the
largest multicenter all-comers TAVR registry with a
second-generation balloon expandable transcatheter
valve. Early and late clinical outcomes and survival
showed that TAVRmatured from a study procedure in a
limited number of well-selected study patients to a
routine treatment, available for a broader population
of patients with aortic stenosis. The safety proﬁle is
sustained, and the clinical beneﬁts of the second-
generation balloon-expandable valve is established in
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668improvements through better patient selection,
optimized implantation technique, and enhanced
device design (25).
The SOURCE XT Registry has demonstrated a large
treatment effect with use of the SAPIEN XT THV in
patients with severe aortic stenosis. At 30 days post-
implantation, NYHA functional class improved,
angina symptoms decreased, and the quality of life
EQ-5D score increased signiﬁcantly. These changes
remained sustained throughout the entire follow-up
period.
STUDY LIMITATIONS. This study was an observa-
tional registry, and patients were selected to receive a
SAPIEN XT valve by an approach on the basis of
technical and clinical features. The primary reasons
for the heart team to offer TAVR and not surgery and
to select 1 delivery approach versus another re-
mained unknown. Also, capturing health and func-
tional status was limited and did not include all
potentially important comorbidities, laboratory, and
functional parameters. Although the transthoracic
echocardiography–derived annulus diameter was re-
ported, the actual imaging tool and the respective
measures of the annulus diameter that were used for
valve size selection were not reported. Finally, the
echocardiographic data were site reported, and no
echocardiography core laboratory was used.a real-world setting. This study clearly demonstrated
that design improvements along with the gained op-
erator’s experience can overcome some early safety
concerns with the ﬁrst-generation balloon expandable
valve.
WHAT IS NEXT: Additional improvement in clinical
outcomes related to vascular complications and par-
avalvular regurgitation may be achieved with further
device iterations and can make TAVR a viable treat-
ment option for a broader subset of patients with
aortic stenosis and intermediate surgical risk.CONCLUSIONS
The SOURCE XT Registry demonstrated appropriate
use of the SAPIEN XT THV in the ﬁrst year post-
commercialization in Europe, where a comprehen-
sive and collaborative program tailored to TAVR had
been successfully established. The safety proﬁle of
the newer generation valve and the clinical beneﬁts
have been established in a real-world setting.
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